Skip to main content
BCAX
NASDAQ Life Sciences

Bicara TherapeuticsによるFORTIFI-HN01の第3流行中測の開始

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$19.39
Mkt Cap
$1.164B
52W Low
$7.8
52W High
$20.25
Market data snapshot near publication time

summarizeSummary

Bicara Therapeuticsは第3流行中測FORTIFI-HN01研究を開始した。この大きな後応は財湯事前司による辿废の輸化を表しています。公司は年終中にチールの発売を起用することが必要です。この引方は行動のポジティブナカタリストになるリスクを庚じることができます。財湯者はt一目にエンロールメントの起用済べとかない後応のデータ・リダウアツを検索しなす。

この発表時点で、BCAXは$19.39で取引されており、市場はNASDAQ、セクターはLife Sciences、時価総額は約$11.6億でした。 52週の取引レンジは$7.80から$20.25でした。 このニュースはポジティブの市場センチメント、重要度スコア8/10と評価されました。 出典：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed BCAX - Latest Insights

BCAX
Mar 30, 2026, 5:30 PM EDT
Filing Type: 10-K
Importance Score:
8
Bicara Therapeutics Reports Increased Losses Amid Pivotal Phase 3 Trial Advancement and Strong Cash Runway
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:59 AM EDT
Source: Reuters
Importance Score:
7
Bicara Therapeutics Reports Q4 Net Loss of $37.4M, Confirms Phase 3 Trial Initiation
Sentiment: Neutral
View Wiseek Article
BCAX
Mar 30, 2026, 7:47 AM EDT
Filing Type: 8-K
Importance Score:
8
Bicara Therapeutics Initiates Pivotal Phase 3 Trial and Secures $161.8M in Oversubscribed Offering, Extending Cash Runway to 2029
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Bicara Therapeutics Kicks Off Phase 3 Trial for FORTIFI-HN01, Targeting Year-End Enrollment
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:25 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
RA Capital Management Invests $40M in Bicara Therapeutics Public Offering, Boosting Stake to 11.5%
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:22 PM EST
Filing Type: 4
Importance Score:
8
RA Capital Management Details $40M Purchase of Bicara Therapeutics Stock and Warrants
Sentiment: Positive
View Wiseek Article
BCAX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Bicara Therapeutics Closes $161.8M Public Offering, Bolstering Cash for Drug Development
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 25, 2026, 9:50 PM EST
Filing Type: 424B5
Importance Score:
8
Bicara Therapeutics Finalizes $150M Public Offering of Common Stock and Warrants at Discount
Sentiment: Negative
View Wiseek Article
BCAX
Feb 24, 2026, 9:47 PM EST
Filing Type: FWP
Importance Score:
8
Bicara Therapeutics Amends Public Offering to Include Pre-Funded Warrants for $150M Capital Raise
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 24, 2026, 4:27 PM EST
Filing Type: 424B5
Importance Score:
7
Bicara Therapeutics Announces $150M Public Offering to Fund Pipeline Advancement
Sentiment: Neutral
View Wiseek Article